Vivos Therapeutics Inc (VVOS) Stock Analysis
Verdict: AVOID
Acute cash burn ($17.6M annual FCF deficit vs $2.03M cash) creates extreme immediate dilution and bankruptcy risk despite 60% gross margins.
Investment score: 22/100
Analysis as of
Is Vivos Therapeutics Inc stock worth reviewing? AI model thesis
The AI model highlights extreme balance sheet distress, where a cash runway of under 1.5 months and negative book value override gross margin expansion and positive referral growth.
7-factor investment score
- Valuation: 20/100 (weight 20%)
- Financial Health: 5/100 (weight 15%)
- Technical Momentum: 10/100 (weight 15%)
- Earnings Quality: 25/100 (weight 15%)
- Insider Sentiment: 60/100 (weight 10%)
- Analyst Consensus: 50/100 (weight 10%)
- Risk-Adjusted Return: 10/100 (weight 15%)
Vivos Therapeutics Inc opportunities and risks
What speaks for VVOS
- Gross margins remain structurally firm at 61.8%
What speaks against VVOS
- Imminent liquidity exhaustion and massive dilution risk
Peers and competitors
| Ticker | P/E | P/S | EV/EBITDA | Gross margin | Net margin | FCF yield |
|---|---|---|---|---|---|---|
| VVOS | n/a | 0.1x | n/a | 59.7% | -122.4% | -658.1% |
| SLDX | n/a | 0.5x | n/a | -21.6% | -258.3% | -300.8% |
| SYRA | 101.0x | 1.3x | 60.7x | 39.3% | 1.6% | 1.0% |
| FPCG | 1.3x | 0.5x | 1.6x | 100.0% | 29.8% | 0.0% |
| AMS | n/a | 0.3x | 7.6x | 17.1% | -5.8% | 37.1% |
| Peer median | 0.4x | 0.5x | 4.6x | 28.2% | -2.1% | 0.5% |
Frequently asked questions about Vivos Therapeutics Inc (VVOS)
Is VVOS stock a good investment?
The cached TradeMates AI model rates Vivos Therapeutics Inc as AVOID with an investment score of 22/100. The AI model highlights extreme balance sheet distress, where a cash runway of under 1.5 months and negative book value override gross margin expansion and positive referral growth. This is algorithmic model output, not personal investment advice.
Is VVOS stock a buy?
The TradeMates model verdict for VVOS is AVOID with an investment score of 22/100. Treat this as a model signal to review, not a personal buy recommendation.